Cargando…

Surgery for Inflammatory Bowel Disease in the Era of Biologic Therapy: A Multicenter Experience from Romania

Background and Objectives: Biologic therapy has fundamentally changed the opportunity of medical treatment to induce and maintain remission in inflammatory bowel disease (IBD). Nevertheless, the rate of surgery is still at a very high rate, profoundly affecting the quality of life. We aimed to analy...

Descripción completa

Detalles Bibliográficos
Autores principales: Pavel, Christopher, Diculescu, Mircea, Constantinescu, Gabriel, Plotogea, Oana-Mihaela, Sandru, Vasile, Meianu, Corina, Dina, Ion, Pop, Ioana, Butuc, Andreea, Mihaila, Mariana, Stan-Ilie, Madalina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9963331/
https://www.ncbi.nlm.nih.gov/pubmed/36837538
http://dx.doi.org/10.3390/medicina59020337
_version_ 1784896226915778560
author Pavel, Christopher
Diculescu, Mircea
Constantinescu, Gabriel
Plotogea, Oana-Mihaela
Sandru, Vasile
Meianu, Corina
Dina, Ion
Pop, Ioana
Butuc, Andreea
Mihaila, Mariana
Stan-Ilie, Madalina
author_facet Pavel, Christopher
Diculescu, Mircea
Constantinescu, Gabriel
Plotogea, Oana-Mihaela
Sandru, Vasile
Meianu, Corina
Dina, Ion
Pop, Ioana
Butuc, Andreea
Mihaila, Mariana
Stan-Ilie, Madalina
author_sort Pavel, Christopher
collection PubMed
description Background and Objectives: Biologic therapy has fundamentally changed the opportunity of medical treatment to induce and maintain remission in inflammatory bowel disease (IBD). Nevertheless, the rate of surgery is still at a very high rate, profoundly affecting the quality of life. We aimed to analyze surgical cases at three major IBD units in order to identify the main risk factors and the impact of biologic therapy on pre- and postsurgical outcomes. Material and Methods: This was a multicenter retrospective cohort study that included 56 patients with IBD-related surgical interventions from 3 tertiary care hospitals in Bucharest, Romania. The study was conducted between January 2017 and June 2021. All data were retrospectively collected from the medical records of the patients and included the age at diagnosis, age at the time of surgery, IBD type and phenotype, biologic therapy before or/and after surgery, timing of biologic therapy initiation, extraintestinal manifestations, type of surgery (elective/emergency), early and long-term postoperative complications and a history of smoking. Results: A low rate of surgical interventions was noted in our cohort (10.3%), but half of these occurred in the first year after the IBD diagnosis. A total of 48% of the surgical interventions had been performed in an emergency setting, which seemed to be associated with a high rate of long-term postoperative complications. We found no statistically significant differences between IBD patients undergoing treatments with biologics before surgery and patients who did not receive biologics before the surgical intervention in terms of the IBD phenotype, type of surgery and postoperative complications. Conclusion: Our study showed that biologics initiated before the surgical intervention did not influence the postoperative complications. Moreover, we demonstrated that patients with Crohn’s disease and no biologics were the most susceptible to having to undergo surgery. Conclusion: In conclusion, the management of patients with IBD requires a multidisciplinary approach that considers an unpredictable evolution.
format Online
Article
Text
id pubmed-9963331
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99633312023-02-26 Surgery for Inflammatory Bowel Disease in the Era of Biologic Therapy: A Multicenter Experience from Romania Pavel, Christopher Diculescu, Mircea Constantinescu, Gabriel Plotogea, Oana-Mihaela Sandru, Vasile Meianu, Corina Dina, Ion Pop, Ioana Butuc, Andreea Mihaila, Mariana Stan-Ilie, Madalina Medicina (Kaunas) Article Background and Objectives: Biologic therapy has fundamentally changed the opportunity of medical treatment to induce and maintain remission in inflammatory bowel disease (IBD). Nevertheless, the rate of surgery is still at a very high rate, profoundly affecting the quality of life. We aimed to analyze surgical cases at three major IBD units in order to identify the main risk factors and the impact of biologic therapy on pre- and postsurgical outcomes. Material and Methods: This was a multicenter retrospective cohort study that included 56 patients with IBD-related surgical interventions from 3 tertiary care hospitals in Bucharest, Romania. The study was conducted between January 2017 and June 2021. All data were retrospectively collected from the medical records of the patients and included the age at diagnosis, age at the time of surgery, IBD type and phenotype, biologic therapy before or/and after surgery, timing of biologic therapy initiation, extraintestinal manifestations, type of surgery (elective/emergency), early and long-term postoperative complications and a history of smoking. Results: A low rate of surgical interventions was noted in our cohort (10.3%), but half of these occurred in the first year after the IBD diagnosis. A total of 48% of the surgical interventions had been performed in an emergency setting, which seemed to be associated with a high rate of long-term postoperative complications. We found no statistically significant differences between IBD patients undergoing treatments with biologics before surgery and patients who did not receive biologics before the surgical intervention in terms of the IBD phenotype, type of surgery and postoperative complications. Conclusion: Our study showed that biologics initiated before the surgical intervention did not influence the postoperative complications. Moreover, we demonstrated that patients with Crohn’s disease and no biologics were the most susceptible to having to undergo surgery. Conclusion: In conclusion, the management of patients with IBD requires a multidisciplinary approach that considers an unpredictable evolution. MDPI 2023-02-10 /pmc/articles/PMC9963331/ /pubmed/36837538 http://dx.doi.org/10.3390/medicina59020337 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Pavel, Christopher
Diculescu, Mircea
Constantinescu, Gabriel
Plotogea, Oana-Mihaela
Sandru, Vasile
Meianu, Corina
Dina, Ion
Pop, Ioana
Butuc, Andreea
Mihaila, Mariana
Stan-Ilie, Madalina
Surgery for Inflammatory Bowel Disease in the Era of Biologic Therapy: A Multicenter Experience from Romania
title Surgery for Inflammatory Bowel Disease in the Era of Biologic Therapy: A Multicenter Experience from Romania
title_full Surgery for Inflammatory Bowel Disease in the Era of Biologic Therapy: A Multicenter Experience from Romania
title_fullStr Surgery for Inflammatory Bowel Disease in the Era of Biologic Therapy: A Multicenter Experience from Romania
title_full_unstemmed Surgery for Inflammatory Bowel Disease in the Era of Biologic Therapy: A Multicenter Experience from Romania
title_short Surgery for Inflammatory Bowel Disease in the Era of Biologic Therapy: A Multicenter Experience from Romania
title_sort surgery for inflammatory bowel disease in the era of biologic therapy: a multicenter experience from romania
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9963331/
https://www.ncbi.nlm.nih.gov/pubmed/36837538
http://dx.doi.org/10.3390/medicina59020337
work_keys_str_mv AT pavelchristopher surgeryforinflammatoryboweldiseaseintheeraofbiologictherapyamulticenterexperiencefromromania
AT diculescumircea surgeryforinflammatoryboweldiseaseintheeraofbiologictherapyamulticenterexperiencefromromania
AT constantinescugabriel surgeryforinflammatoryboweldiseaseintheeraofbiologictherapyamulticenterexperiencefromromania
AT plotogeaoanamihaela surgeryforinflammatoryboweldiseaseintheeraofbiologictherapyamulticenterexperiencefromromania
AT sandruvasile surgeryforinflammatoryboweldiseaseintheeraofbiologictherapyamulticenterexperiencefromromania
AT meianucorina surgeryforinflammatoryboweldiseaseintheeraofbiologictherapyamulticenterexperiencefromromania
AT dinaion surgeryforinflammatoryboweldiseaseintheeraofbiologictherapyamulticenterexperiencefromromania
AT popioana surgeryforinflammatoryboweldiseaseintheeraofbiologictherapyamulticenterexperiencefromromania
AT butucandreea surgeryforinflammatoryboweldiseaseintheeraofbiologictherapyamulticenterexperiencefromromania
AT mihailamariana surgeryforinflammatoryboweldiseaseintheeraofbiologictherapyamulticenterexperiencefromromania
AT staniliemadalina surgeryforinflammatoryboweldiseaseintheeraofbiologictherapyamulticenterexperiencefromromania